Results 161 to 170 of about 32,890 (266)

Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn’s disease patients

open access: yesScientific Reports
Long-term remission in Crohn’s disease (CD) remains challenging. While ustekinumab effectively induces remission, strategies to enhance its maintenance efficacy are urgently needed.
Haixia Ren   +15 more
doaj   +1 more source

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis

open access: yesPatient Preference and Adherence
Maryia Zhdanava,1 Sumesh Kachroo,2 Aditi Shah,1 Zhijie Ding,2 Patrick Lefebvre,1 Ruizhi Zhao,2 Caroline Kerner,2 Dominic Pilon1 1Analysis Group, Inc, Montréal, QC, Canada; 2Janssen Scientific Affairs, LLC, Horsham, PA, USACorrespondence: Maryia Zhdanava,
Zhdanava M   +7 more
doaj  

Psoriasis treatment with biologics: beyond tumor necrosis factor α inihibitors – The present and the future [PDF]

open access: yes, 2012
A psoríase é uma doença inflamatória crónica multissistémica, mediada por células T, com elevado grau de morbilidade. A investigação na área da psoríase tem sido intensa, resultando num conhecimento mais porme- norizado da sua patogenia, e consequente ...
Carvalho, S., Selores, M., Torres, T.
core  

Experiencia en el Hospital Universitario Basurto con secukinumab para el tratamiento de la psoriasis moderada-grave [PDF]

open access: yes, 2018
[ES] Hemos realizado un estudio descriptivo retrospectivo para valorar la respuesta y la seguridad del tratamiento con secukinumab, un biológico anti IL-17, durante 52 semanas en pacientes con psoriasis moderada-grave.
Orbea Sopeña, Ana
core  

Australian Real‐World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium

open access: yesJGH Open
Background Ustekinumab is an effective therapy for the management of Crohn's disease. Australia is unique, as ustekinumab can be prescribed as first‐line biologic therapy, and there is high concomitant immunomodulator use.
Yoon‐Kyo An   +29 more
doaj   +1 more source

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers

open access: yes
HemaSphere, Volume 10, Issue 4, April 2026.
Allison M. Bock   +39 more
wiley   +1 more source

Engagement and retention with remote monitoring in psoriasis: Findings from the mySkin study

open access: yes
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page e274-e277, April 2026.
Weiyu Ye   +22 more
wiley   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

open access: yes, 2020
Bathon, J.   +16 more
core   +1 more source

Long‐term safety and efficacy in paediatric psoriasis: Remaining challenges

open access: yes
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 558-559, April 2026.
Catherine Droitcourt, Ninon Le Goaziou
wiley   +1 more source

Home - About - Disclaimer - Privacy